RBC puts Cubist at outperform

Cubist Pharmaceuticals was rated at outperform, above average risk, by RBC Capital Markets analyst Jason Kantor. RBC believes Cubist will post strong Cubicin sales. Based on IMS sales growth, the analyst raised his second-quarter Cubicin estimate to $48.5 million from $45.5 million and full-year 2006 to $202 million from $197 million. Shares of the Lexington, Mass.-based biopharmaceutical company were up 34 cents, or 1.37%, at $25.18 on volume of 1,229,047 shares versus the three-month running average of 1,119,170 shares. (Nasdaq: CBST)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.